293 related articles for article (PubMed ID: 17442100)
1. Safety and efficacy of a caspofungin-based combination therapy for treatment of proven or probable aspergillosis in pediatric hematological patients.
Cesaro S; Giacchino M; Locatelli F; Spiller M; Buldini B; Castellini C; Caselli D; Giraldi E; Tucci F; Tridello G; Rossi MR; Castagnola E
BMC Infect Dis; 2007 Apr; 7():28. PubMed ID: 17442100
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies.
Kontoyiannis DP; Hachem R; Lewis RE; Rivero GA; Torres HA; Thornby J; Champlin R; Kantarjian H; Bodey GP; Raad II
Cancer; 2003 Jul; 98(2):292-9. PubMed ID: 12872348
[TBL] [Abstract][Full Text] [Related]
3. Caspofungin as first line therapy of pulmonary invasive fungal infections in 32 immunocompromised patients with hematologic malignancies.
Candoni A; Mestroni R; Damiani D; Tiribelli M; Michelutti A; Silvestri F; Castelli M; Viale P; Fanin R
Eur J Haematol; 2005 Sep; 75(3):227-33. PubMed ID: 16104879
[TBL] [Abstract][Full Text] [Related]
4. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis.
Maertens J; Glasmacher A; Herbrecht R; Thiebaut A; Cordonnier C; Segal BH; Killar J; Taylor A; Kartsonis N; Patterson TF; Aoun M; Caillot D; Sable C;
Cancer; 2006 Dec; 107(12):2888-97. PubMed ID: 17103444
[TBL] [Abstract][Full Text] [Related]
5. [Clinical characteristics and efficacy of anti-Aspergillus therapy in patients with hematological malignancies and invasive aspergillosis].
Li Y; Gao L; Wang LL; Wang QS; Li HH; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Oct; 19(5):1289-93. PubMed ID: 22040990
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients.
Betts R; Glasmacher A; Maertens J; Maschmeyer G; Vazquez JA; Teppler H; Taylor A; Lupinacci R; Sable C; Kartsonis N
Cancer; 2006 Jan; 106(2):466-73. PubMed ID: 16353208
[TBL] [Abstract][Full Text] [Related]
7. Caspofungin for the treatment of invasive fungal disease in hematological patients (ProCAS Study).
Jarque I; Tormo M; Bello JL; Rovira M; Batlle M; Julià A; Tabares S; Rivas C; Fernández-Sevilla A; García-Boyero R; Debén G; González-Campos J; Capote FJ; Sanz MA;
Med Mycol; 2013 Feb; 51(2):150-4. PubMed ID: 22712457
[TBL] [Abstract][Full Text] [Related]
8. Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin.
Aliff TB; Maslak PG; Jurcic JG; Heaney ML; Cathcart KN; Sepkowitz KA; Weiss MA
Cancer; 2003 Feb; 97(4):1025-32. PubMed ID: 12569602
[TBL] [Abstract][Full Text] [Related]
9. Successful antifungal combination therapy with voriconazole and caspofungin.
Schuster F; Moelter C; Schmid I; Graubner UB; Kammer B; Belohradsky BH; Führer M
Pediatr Blood Cancer; 2005 Jun; 44(7):682-5. PubMed ID: 15700260
[TBL] [Abstract][Full Text] [Related]
10. Increasing incidence of invasive aspergillosis in pediatric hematology oncology patients over the last decade: a retrospective single centre study.
Rubio PM; Sevilla J; González-Vicent M; Lassaletta A; Cuenca-Estrella M; Díaz MA; Riesco S; Madero L
J Pediatr Hematol Oncol; 2009 Sep; 31(9):642-6. PubMed ID: 19684521
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy.
Maertens J; Raad I; Petrikkos G; Boogaerts M; Selleslag D; Petersen FB; Sable CA; Kartsonis NA; Ngai A; Taylor A; Patterson TF; Denning DW; Walsh TJ;
Clin Infect Dis; 2004 Dec; 39(11):1563-71. PubMed ID: 15578352
[TBL] [Abstract][Full Text] [Related]
12. Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin.
Raad II; Hanna HA; Boktour M; Jiang Y; Torres HA; Afif C; Kontoyiannis DP; Hachem RY
Leukemia; 2008 Mar; 22(3):496-503. PubMed ID: 18094720
[TBL] [Abstract][Full Text] [Related]
13. A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients.
Zaoutis TE; Jafri HS; Huang LM; Locatelli F; Barzilai A; Ebell W; Steinbach WJ; Bradley J; Lieberman JM; Hsiao CC; Seibel N; Laws HJ; Gamba M; Petrecz M; Taylor AF; Strohmaier KM; Chow JW; Kartsonis NA; Ngai AL
Pediatrics; 2009 Mar; 123(3):877-84. PubMed ID: 19255017
[TBL] [Abstract][Full Text] [Related]
14. Combination antifungal treatment for invasive fungal disease after hematopoietic stem cell transplantation in children with hematological disorders.
Qiu KY; Liao XY; Fang JP; Xu HG; Li Y; Huang K; Zhou DH
Transpl Infect Dis; 2019 Jun; 21(3):e13066. PubMed ID: 30859662
[TBL] [Abstract][Full Text] [Related]
15. Clinical experience of the use of voriconazole, caspofungin or the combination in primary and salvage therapy of invasive aspergillosis in haematological malignancies.
Raad II; Zakhem AE; Helou GE; Jiang Y; Kontoyiannis DP; Hachem R
Int J Antimicrob Agents; 2015 Mar; 45(3):283-8. PubMed ID: 25455847
[TBL] [Abstract][Full Text] [Related]
16. An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients.
Viscoli C; Herbrecht R; Akan H; Baila L; Sonet A; Gallamini A; Giagounidis A; Marchetti O; Martino R; Meert L; Paesmans M; Ameye L; Shivaprakash M; Ullmann AJ; Maertens J;
J Antimicrob Chemother; 2009 Dec; 64(6):1274-81. PubMed ID: 19841031
[TBL] [Abstract][Full Text] [Related]
17. Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience.
Lass-Flörl C; Griff K; Mayr A; Petzer A; Gastl G; Bonatti H; Freund M; Kropshofer G; Dierich MP; Nachbaur D
Br J Haematol; 2005 Oct; 131(2):201-7. PubMed ID: 16197450
[TBL] [Abstract][Full Text] [Related]
18. A retrospective nationwide case study on the use of a new antifungal agent: patients treated with caspofungin during 2001-2004 in Finland.
Anttila VJ; Salonen J; Ylipalosaari P; Koivula I; Riikonen P; Nikoskelainen J
Clin Microbiol Infect; 2007 Jun; 13(6):606-12. PubMed ID: 17378926
[TBL] [Abstract][Full Text] [Related]
19. Paradoxical increase in circulating Aspergillus antigen during treatment with caspofungin in a patient with pulmonary aspergillosis.
Klont RR; Mennink-Kersten MA; Ruegebrink D; Rijs AJ; Blijlevens NM; Donnelly JP; Verweij PE
Clin Infect Dis; 2006 Aug; 43(3):e23-5. PubMed ID: 16804836
[TBL] [Abstract][Full Text] [Related]
20. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis.
Denning DW; Marr KA; Lau WM; Facklam DP; Ratanatharathorn V; Becker C; Ullmann AJ; Seibel NL; Flynn PM; van Burik JA; Buell DN; Patterson TF
J Infect; 2006 Nov; 53(5):337-49. PubMed ID: 16678903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
